Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2.
Garot P, Neylon A, Morice MC, Tamburino C, Bleiziffer S, Thiele H, Scholtz S, Schramm R, Cockburn J, Cunnington M, Wolf A, Barbanti M, Tchetché D, Pagnotta P, Gilard M, Bedogni F, Van Belle E, Vasa-Nicotera M, Chieffo A, Bogaerts K, Hengstenberg C, Capodanno D.
Garot P, et al. Among authors: bogaerts k.
EuroIntervention. 2022 Aug 19;18(6):503-513. doi: 10.4244/EIJ-D-21-01048.
EuroIntervention. 2022.
PMID: 35450838
Free PMC article.
Clinical Trial.